
Possible Treatments for Covid-19
The FDA has been working closely with other government agencies and academic centers that are investigating the use of the drug CHLOROQUINE, which is already approved for treating malaria, lupus and rheumatoid arthritis, to determine whether it can be used to treat patients with mild-to-moderate COVID-19 to potentially reduce the duration of symptoms, as well as viral shedding, which can help prevent the spread of disease. Studies are underway to determine the efficacy of using…
Published

Point of care testing for Covid-19
The test we’re authorizing today will be able to provide Americans with results within hours, rather than days like the existing tests, and the company plans to roll it out by March 30, which is an incredibly rapid timeline for such an effort. With new tools like point-of-care diagnostics, we are moving into a new phase of testing, where tests will be much more easily accessible to Americans who need them. With the development of…
Published

Cases of Covid-19 in mainland China
We believe the actual number of 2019-nCoV cases in mainland China is likely much higher than that reported to date. Specifically, we estimate there to be around 58,000 cumulative cases of 2019-nCoV in mainland China by the end of January (as of January 31, the reported cases are close to 12,000). This estimate is in line with our previous analysis on January 25, which estimated the proportion of reported to estimated cases to be close…
Published

The Incubation Period of COVID-19
There were 181 confirmed cases with identifiable exposure and symptom onset windows to estimate the incubation period of COVID-19. The median incubation period was estimated to be 5.1 days, and 97.5% of those who develop symptoms will do so within 11.5 days of infection. These estimates imply that, under conservative assumptions, 1% (1 in 100) of infected cases will develop symptoms after 14 days of active monitoring or quarantine. AIM
Published

